Paion cardiovascular, neurology news

Paion issued an update for its ongoing restructuring will now reduce headcount to 11 employees. Late last year, Paion said it would reduce headcount by 19 (70%) to eight to reduce costs and focus on its core business, including out-licensing remimazolam, a GABA A receptor modulator in Phase IIb...